NCT00664781已完成2 期
A Cancer Research UK Phase II Proof of Principle Trial of the Activity of the PARP-1 Inhibitor, AG-014699, in Known Carriers of a BRCA 1 or BRCA 2 Mutation With Locally Advanced or Metastatic Breast or Advanced Ovarian Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 78
- 试验地点
- 14
- 主要终点
- Assessment of antitumor activity according to RECIST using tumor size measured clinically or radiologically with CT scan, MRI, plain x-ray, or other imaging techniques
研究概览
简要总结
RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in treating patients with locally advanced or metastatic breast cancer or advanced ovarian cancer.
详细描述
OBJECTIVES:
Primary
- Assessment of Anti tumour activity to PARP-1 inhibitor rucaparib in patients with locally advanced or metastatic breast or advanced ovarian cancer shown to express the BRCA 1 or 2 mutations.
- To evaluate the toxicity of treatment with Rucaparib in these population's.
Secondary
- To evaluate the time to progression and overall survival in patients treated with this drug.
- To study pharmacokinetics of this drug in these patient populations.
- To evaluate the Poly(ADP-ribose) polymerase (PARP) activity in peripheral blood lymphocytes from BRCA 1 and 2 heterozygotic patients.
- To determine a tolerable and effective dosing regimen of the Rucaparib oral formulation.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All stages of the study (IV and oral):
- •Patients must be proven known carriers of a mutation of BRCA1 or BRCA2 or considered to be highly likely to be carriers of a BRCA1 or 2 mutation* (score of ≥ 20 as per Manchester criteria) and have histologically documented locally advanced or metastatic breast cancer or advanced ovarian cancer.
- •*Patients considered highly likely to be carriers will be tested after consenting and a BRCA1 or 2 mutation must be confirmed for the patient to be eligible to receive treatment.
- •Oral stage 1 only:
- •In addition to the above, patients with high grade serous ovarian cancer with unknown BRCA status may be entered into oral stage
- •Patients with ovarian cancer (including epithelial, fallopian tube cancer and primary peritoneal cancer) who have had no more than 5 prior chemotherapy regimens in the last 5 years. For the BRCA carriers > 2 months must have elapsed since their last treatment with a carboplatin- or cisplatin-containing regimen or for high grade serous ovarian cancer patients ≥ 6 months.
- •Patients with breast cancer who have had no more than 5 prior chemotherapy regimens in the last 5 years.
- •Measurable disease as measured by X-ray, computerised tomography (CT), or MRI scan as defined by RECIST criteria. These measurements must be done within 4 weeks of the patient going on study. Clinical measurements must be done within one week of the patient going on study. Patients with bone disease must have other measurable disease for evaluation. Previously irradiated lesions cannot be used for measurable disease.
- •Life expectancy of at least 12 weeks
- •World Health Organisation (WHO) performance status of 0 or 1 (Appendix 1)
- •Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week before the patient goes on study.
- •Lab Test Value Required Haemoglobin (Hb) ≥9.0 g/dl Neutrophils ≥1.5 x 10^9/L Platelets (Plts) ≥100 x 10^9/L Serum bilirubin ≤1.5 x upper normal limit Alanine amino-transferase (ALT) and/or ≤ 2.5 x upper limit of normal (ULN) aspartate amino-transferase (AST) unless due to tumour in which case up to 5 x ULN is permissible Glomerular Filtration Rate (GFR) calculated either by the Wright formula ≥50 ml/min or Cockcroft-Gault formula or by isotope clearance measurement
- •18 years or over
- •Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up
排除标准
- •Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy, chemotherapy, biological agents or investigational agents during the previous 4 weeks (6 weeks for nitrosoureas and Mitomycin-C) before treatment.
- •Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the Drug Development Office (DDO) should not exclude the patient.
- •Known brain metastases.
- •Female patients able to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use two highly effective forms of contraception (oral, injected or implanted hormonal contraception and condom, have an intrauterine device and condom, diaphragm with spermicidal gel and condom, or are surgically sterilised) 4 weeks before entering the trial, during the trial and for 6 months afterwards are considered eligible.
- •Male patients with partners of child-bearing potential (unless they agree to use one form of highly effective contraception such as a barrier method of condom plus spermicide during the trial and for 6 months afterwards).
- •Major thoracic and/or abdominal surgery in the preceding 4 weeks from which the patient has not recovered.
- •At high medical risk because of non-malignant systemic disease including active uncontrolled infection.
- •Concurrent malignancies at other sites, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin and concurrent breast and ovarian carcinoma. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, are eligible for the study.
- •Patients with active or unstable cardiac disease or history of myocardial infarction within 6 months. Patients with cardiovascular signs or symptoms should have a MUGA scan or echocardiogram, and those patients with left ventricular ejection fraction (LVEF) below the institutional limit of normal should be excluded.
- •Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
- •Patients who have already received a PARP inhibitor.
结局指标
主要结局
Assessment of antitumor activity according to RECIST using tumor size measured clinically or radiologically with CT scan, MRI, plain x-ray, or other imaging techniques
Safety profile
次要结局
- Time to progression and overall survival
- Plasma levels measured by Liquid Chromatography/Mass Spectrometry/Mass Spectrometry
- Poly(ADP-ribose) polymerase (PARP) activity measured ex vivo using validated assays
- To determine the optimal oral dosing regimen, based on the assessment of antitumor activity and the safety profile
研究者
研究点 (14)
Loading locations...
相似试验
已完成
1 期
Olaparib and Temozolomide in Treating Patients With Relapsed GlioblastomaBrain and Central Nervous System TumorsNCT01390571Cancer Research UK34
终止
2 期
Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung CancerLung CancerNCT00726986Afshin Dowlati, MD18
终止
2 期
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney CancerRecurrent Renal Cell CancerStage IV Renal Cell CancerClear Cell Renal Cell CarcinomaNCT00126659National Cancer Institute (NCI)10
已完成
2 期
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or CarboplatinPeritoneal Cavity CancerOvarian CancerNCT00436644Mayo Clinic18
已完成
1 期
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast CancerBreast CancerNCT00755885Cancer Research UK77